摘要
新型钙增敏剂左西孟旦对长期服用β受体阻滞剂等药物的心力衰竭患者疗效较好;单用或与地高辛合用对心力衰竭都有一定疗效,口服没有静脉给药疗效明显;用于心脏手术患者可以缩短术后康复时间、降低术后心房颤动发生率,对缺血及再灌注损伤心肌也有保护作用。钙增敏剂盐酸椒苯酮胺也有心肌保护作用,已经完成127例Ⅰ期临床试验,结果显示有良好的耐受性,但疗效及安全性有待进一步确定。本文综述了近年来左西孟旦及盐酸椒苯酮胺的研究进展。
Calcium sensitizer levosimendan has good clinical effect for heart failure patients with long-term administration of β-receptor blocker.The efficiency of levosimendan combined with digoxigenin is similar to that of levosimendan alone in treatment of heart failure.Compared with oral administration,the intravenous route is more effective.Administrating levosimendan for patients after heart surgery can shorten the recovery time and decrease the incidence of atrial fibrillation.Levosimendan also has cardioprotective effects on myocardium injured by ischemia and reperfusion.Piperphentonamine（PPTA）also has the effects of cardioprotection.PhaseⅠclinical trial for PPTA has been finished in 127 healthy volunteers.The result shows PPTA has better tolerance and the human pharmacokinetic parameters in healthy subjects are in accordance with animal.The safety and efficacy of PPTA need to be defined by further clinical trials.This article summaries the clinical research advances related to calcium sensitizers levosimendan and piperphentonamine in recent years.
出处
《国际药学研究杂志》
CAS
2010年第1期32-35,共4页
Journal of International Pharmaceutical Research
基金
广州市科技攻关重点项目(2002Z2-E4041)
关键词
钙增敏剂
强心药
心肌保护
左西孟旦
椒苯酮胺
临床试验
calcium sensitizer cardiotonic cardioprotection levosimendan piperphentonamine clinical trial
